Sixty previously untreated oral cancer patients received intra-arterial chemotherapy as preoperative treatment: 18 patients were given cisplatin-Ebewe, 16 received farmorubicin and 26 patients were treated with a combination of these drugs. Surgical intervention was performed on average 4-5 days after completion of the intra-arterial infusion. In the group treated with cisplatin-Ebewe, the vascular lesions were minimal in 6/18 cases and moderate in 1/18 case. No lesions could be observed in 11/18 cases. Tumour regression was complete clinically in 4/18 cases, and histologically in 2/18 cases; 9/18 patients exhibited a partial response and 5/18 a minor response. In the group given farmorubicin alone, vascular injury was minimal in 4/16, moderate in 3/16 and serious in 3/16 cases. No vascular lesions were demonstrated in 6/16 patients; 5/16 patients gave a clinically complete response, 2/16 patients a histologically complete response, 8/16 cases a partial response, and 3/16 cases a minor response. In the group treated with the cisplatin-Ebewe and farmorubicin combination vascular lesions were minimal in 10/26, moderate in 5/26 and serious in 4/26 cases. No lesions were found in 7/26 cases. A complete tumour response was observed clinically in 6/26 cases and histologically in 3/26 cases, with a partial response in 15/26, and a minor response in 5/26 patients. Cisplatin-Ebewe seemed to be the more advantageous drug, causing fewer thrombotic complications in the vascular bed.
|Number of pages||6|
|Journal||Regional Cancer Treatment|
|Publication status||Published - Jan 1 1991|
ASJC Scopus subject areas